Fundz

Aditxt

Richmond, Virginia, United States · Biotechnology, Health Care · 26 employees

Aditxt is developing technologies specifically focused on improving the health of the immune system through immune monitoring and reprogramming. Aditxt’s immune monitoring technology is designed to provide a personalized comprehensive profile of the immune system. Aditxt’s immune reprogramming technology is currently at the pre-clinical stage and is designed to retrain the immune system to induce

Funding history

  • Funding Round — $6.0M — Jan 2024
  • Funding Round — $10.0M — Sep 2023
  • Series seed — $2.0M — Aug 2022
  • Funding Round — $6.0M — Jan 2021
  • Series pre-seed — $110K — Dec 2018

Recent signals

  • Jun 10, 2026: Acquired Aditxt to merge with Ignite Proteomics, forming new entity
  • May 27, 2026: SEC 8-K (5.01): On May 27, 2026, Aditxt, Inc. received a notification from Nasdaq regarding its failure to meet continued listing requirements due to stockholders' equity of $(35,174,386) as reported in its recent 10-Q filing for the period ending March 31, 2026. This deficiency places the company's stock listing at risk on The Nasdaq Capital Market under Rule 5550(b)(1). The company does not meet alternative listing standards, including minimum market capitalization or net income benchmarks, which could impact investor confidence and trading activity.
  • Mar 19, 2026: Aditxt Appoints Jeff Busch as Chief Executive Officer of Ignite Proteomics
  • Mar 13, 2026: Acquired Aditxt acquires Ignite Proteomics for cancer care
  • Oct 20, 2025: SEC 8-K (1.02): On October 20, 2025, Aditxt, Inc. received a notice of termination from Evofem Biosciences, Inc. regarding the Amended and Restated Agreement and Plan of Merger, previously dated July 12, 2024, and subsequently amended several times up to August 26, 2025. The termination is effective immediately, citing the end date passing and the failure to obtain necessary shareholder approval at a special meeting held on the same date. Importantly, Aditxt will not incur any termination fees or penalties associated with this termination, which potentially allows the company to focus on alternative strategic initiatives without financial liability from the merger attempt.
  • Oct 03, 2025: Aditxt Appoints Christopher J. Porcelli as General Counsel and Chief People Officer
  • Sep 24, 2024: Acquired Aditxt announces acquisition of Evofem Biosciences to enhance its health innovation platform
  • Aug 29, 2024: Aditxt Announces Partnership Agreements with Appili Therapeutics and Evofem Biosciences

See plans & pricing → Track Aditxt’s funding, hiring, and signals — with verified contacts — on Fundz.